Stéphane Bancel, Endpoints JPM 2020 (Jeff Rumans)

Mod­er­na eyes $500M sec­ondary of­fer­ing on up­beat coro­n­avirus vac­cine up­date — al­most ready for the clin­ic

Among the army of biotechs that threw them­selves in­to the gold rush for 2019-nCoV vac­cines or ther­a­pies, Mod­er­na emerged as one of the most le­git­i­mate con­tenders: The NIH had signed it on as a part­ner, demon­strat­ing con­fi­dence in its mes­sen­ger RNA plat­form to pro­duce a vac­cine rapid­ly.

That has giv­en the Cam­bridge, MA-based biotech a nice bump on its uni­corn val­u­a­tion. And CEO Stéphane Ban­cel is seiz­ing it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.